Trastuzumab is primarily given to women with HER2-overexpressing breast cancer to block HER2 signaling, and in doing so it suppresses autophagy in cardiomyocytes to trigger accumulation of toxic reactive oxygen species (ROS) within cardiomyocytes [10]. The gene discussed is ERBB2; the disease is breast carcinoma.